Skip to main content
SpringerLink
Log in

Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Several concerns have emerged on the higher risk of in-stent thrombosis after drug-eluting stent (DES) implantation, especially in the setting of STEMI patients. Few data have even been reported in high-risk patients, such as those with anterior MI. Therefore this represents the aim of the current study.

Methods

The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL). We examined all completed randomized trials of DES for STEMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, stenting, DES, sirolimus-eluting stent (SES), Cypher, paclitaxel-eluting stent (PES), Taxus. No language restrictions were enforced.

Results

Individual patient’s data were obtained from 11 out of 13 trials, including a total of 2,782 patients with anterior MI [1,739 or 62.5 % randomized to DES and 1,043 or 37.5 % randomized to bare-metal stent (BMS)]. At long-term follow-up, no significant benefit was observed with DES as compared to BMS in terms of mortality [9.8 vs 10.9 %, HR (95 % CI) = 0.81 (0.61, 1.07), p = 0.13, p heterogeneity = 0.18], reinfarction [8.8 vs 6.4 %, respectively; HR (95 % CI) = 1.14 (0.80, 1.61), p = 0.47, p heterogeneity = 0.82], and stent thrombosis [5.6 vs 5 %, OR (95 % CI) = 0.88 (0.59, 1.30), p = 0.51, p heterogeneity = 0.65], whereas DES was associated with a significant reduction in terms of target-vessel revascularization (TVR) [13.7 vs 23.4 %; OR (95 % CI) = 0.56 (0.46, 0.69), p < 0.0001, p het = 0.81] that was observed at both early (within 1 year) [7 vs 14.7 %, HR (95 % CI) = 0.56 (0.46, 0.69), p < 0.0001, p het = 0.81] and late (>1 year) follow-up [7.2 vs 9 %, HR (95 % CI) = 0.67 (0.47, 0.96), p = 0.03, p het = 0.96].

Conclusions

This study showed that among patients with anterior STEMI undergoing primary angioplasty, SES and PES, as compared to BMS, are associated with a significant reduction in TVR at long-term follow-up. No concerns were found with the use of first-generation DES in terms of mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. De Luca G, Cassetti E, Marino P (2009) Percutaneous coronary intervention-related time delay, patient’s risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 27:712–719

    Article  PubMed  Google Scholar 

  2. De Luca G, Suryapranata H, Marino P (2008) Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 50:352–382

    Article  PubMed  Google Scholar 

  3. Vandecasteele EH, De Buyzere M, Gevaert S, de Meester A, Convens C, Dubois P, Boland J, Sinnaeve P, De Raedt H, Vranckx P, Coussement P, Evrard P, Beauloye C, Renard M, Claeys MJ (2013) Reperfusion therapy and mortality in octogenarian STEMI patients: results from the Belgian STEMI registry. Clin Res Cardiol 102(11):837–845

    PubMed  Google Scholar 

  4. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, De Carlo M, Rakowski T, Gyongyosi M, Dudek D (2011) Early glycoprotein IIb–IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 9:2361–2370

    Article  Google Scholar 

  5. De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van’t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93:820–823

    PubMed  Google Scholar 

  6. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R, On behalf of the HORIZONS-AMI Trial Investigators (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet [Epub ahead of print]

  7. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957–966

    Article  CAS  PubMed  Google Scholar 

  8. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, Chiariello M, Marino P (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126:37–44

    Article  PubMed  Google Scholar 

  9. De Luca G, Suryapranata H, van’t Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosselink AT, de Boer MJ (2009) Routine stenting vs. balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion. J Cardiovasc Med 10:22–26

    Article  Google Scholar 

  10. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, TAXUS-IV Investigators et al (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221–231

    Article  CAS  PubMed  Google Scholar 

  11. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P (2009) Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 133:213–222

    Article  PubMed  Google Scholar 

  12. De Luca G, Valgimigli M, Spaulding C, Menichelli M, Brunner-La Rocca HP, van der Hoeven BL, Di Lorenzo E, Diaz de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini R, Stone GW (2009) Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis 28:200–210

    Article  CAS  PubMed  Google Scholar 

  13. Piccolo R, Cassese S, Galasso G, Niglio T, De Rosa R, De Biase C, Piscione F (2012) Long-term clinical outcomes following sirolimus-eluting stent implantation inpatients with acute myocardial infarction. A meta-analysis of randomized trials. Clin Res Cardiol 101:885–893

    CAS  PubMed  Google Scholar 

  14. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW, Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation (2012) Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611–21

  15. Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 31:61–66

    Article  Google Scholar 

  16. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–9, W64

    Google Scholar 

  17. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M, STRATEGY Investigators (2009) The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 54:1900–1901

    Article  PubMed  Google Scholar 

  18. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ (2011) 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 4:24–29

    Article  PubMed  Google Scholar 

  19. Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, Beatt K, Tirouvanziam A, Polonski L, Stella PR, Clugston R, Fajadet J, de Boisgelin X, Bode C, Carrié D, Erglis A, Merkely B, Hosten S, Cebrian A, Wang P, Stoll HP, Henry P (2011) Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 4:14–23

    Article  PubMed  Google Scholar 

  20. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G (2009) Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or sirolimus-eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 158:e43–e50

    Article  PubMed  Google Scholar 

  21. Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R (2010) Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol 55:810–814

    Article  PubMed  Google Scholar 

  22. Pittl U, Kaiser C, Brunner-La Rocca HP, BASKET Investigators (2006) Safety and efficacy of drug eluting stents versus bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction: a prospective randomized study. Eur Heart J 27(Abstract Suppl):650

    Google Scholar 

  23. Sardella G, Paroli M, Mancone M (2006) Impact of paclitaxel-eluting stent implantation in patients with STEMI on anti-inflammatory IL-10-producing T regulatory 1 (Tr1) cells. Eur Heart J 27(Abstract Suppl):831

    Google Scholar 

  24. Pasceri V, Granatelli A, Pristipino C (2003) A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: preliminary results. Am J Cardiol 92(Suppl 6A):1L

    Google Scholar 

  25. Tierala I The Helsinki Area Acute Myocardial Infarction treatment re-evaluation: should the patient get a drug-eluting or a normal stent (HAAMU-STENT) study. http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1453095

  26. Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, Bootsma M, Zeppenfeld K, van der Wall EE, Schalij MJ (2010) Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Am J Cardiol 106:4–12

    Article  CAS  PubMed  Google Scholar 

  27. Chechi T, Vittori G, Biondi Zoccai GG, Vecchio S, Falchetti E, Spaziani G, Baldereschi G, Giglioli C, Valente S, Margheri M (2007) Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 20:282–291

    Article  PubMed  Google Scholar 

  28. Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S (2010) Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 56:641–645

    Article  PubMed  Google Scholar 

  29. Karjalainen. TITAX AMI Trial. http://www.tctmd.com/csportal/appmanager/tctmd/tct2007?_nfpb=true&_pageLabel=TCT2007Content&hdCon=1518259

  30. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R, Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators (2008) Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299:1788–1799

    Article  CAS  PubMed  Google Scholar 

  31. Díaz de la Llera LS, Ballesteros S, Nevado J, Fernández M, Villa M, Sánchez A, Retegui G, García D, Martínez A (2007) Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 154:164.e1–6

  32. George BS, Voorhees WD 3rd, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE et al (1993) Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 22:135–143

    Article  CAS  PubMed  Google Scholar 

  33. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al (1996) A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089

    Article  CAS  PubMed  Google Scholar 

  34. The Epistent investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92

    Article  Google Scholar 

  35. Capozzolo C, Piscione F, De Luca G, Cioppa A, Mazzarotto P, Leosco D, Golino P, Indolfi C, Chiariello M (2001) Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv 53:464–473

    Article  CAS  PubMed  Google Scholar 

  36. Suryapranata H, van’t Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F (1998) Randomised comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 97: 2502–2505

    Google Scholar 

  37. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF (1998) A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence randomised elective stenting in acute coronary occlusion (FRESCO) trial. J Am Coll Cardiol 31:1234–1239

    Article  CAS  PubMed  Google Scholar 

  38. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130

    Article  CAS  PubMed  Google Scholar 

  39. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS et al (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113:2803–2809

    Article  CAS  PubMed  Google Scholar 

  40. Kernis SJ, Cohen D, Rein K (2005) Clinical outcome associated with use of drug-eluting stents compared with bare metal stent for primary percutaneous intervention. Am J Cardiol 96(suppl 7A):47H

    Google Scholar 

  41. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, Goodman SG, Avezum A, Huang W, Gore JM, Global Registry of Acute Coronary Events (GRACE) Investigators (2009) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 30:321–329

    Article  PubMed  Google Scholar 

  42. De Luca G, Ernst N, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT et al (2006) Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 151:1256–9

    Google Scholar 

  43. Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew TC, Parise H, Sergie Z, Mehran R, Stone GW (2013) Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery. Am J Cardiol 112:753–760

    Article  PubMed  Google Scholar 

  44. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW (2012) Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 380:1482–1489

    Article  CAS  PubMed  Google Scholar 

  45. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S, COMFORTABLE AMI Trial Investigators (2012) Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308(8):777–787

    Article  PubMed  Google Scholar 

  46. Gomez-Lara J, Brugaletta S, Gomez-Hospital JA, Ferreiro JL, Roura G, Romaguera R, Martin-Yuste V, Masotti M, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Serruys P, Sabate M, Cequier A (2013) Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial. Am Heart J 166:119–126

    Article  CAS  PubMed  Google Scholar 

  47. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schömig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101:461–7

    Google Scholar 

  48. De Luca G, Suryapranata H, de Boer MJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Ernst N, van’t Hof AW, Ongoing Tirofiban In Myocardial Infarction Evaluation (On-TIME) study group (2007) Combination of electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty. Int J Cardiol 117:232–7

    Google Scholar 

  49. De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, van’t Hof AW (2005) Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 150:1248–1254

    Article  PubMed  Google Scholar 

  50. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G, Marino P, Sinigaglia F, De Luca G (2013) Benefits from new ADP-antagonists as compared to clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol [Epub ahead of print]

  51. Theidel U, Asseburg C, Giannitsis E, Katus H (2013) Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 102(6):447–458

    PubMed  Google Scholar 

Download references

Acknowledgments

Prof. De Luca had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study has no financial support. All authors declare that they participated in the study and that they have seen and approved the final version.

Author information

Authors and Affiliations

  1. Division of Cardiology, Ospedale “Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 24100, Novara, Italy

    Giuseppe De Luca

  2. Centro di Biotecnologie per la Ricerca Medica Applicata (BRMA), Eastern Piedmont University, Novara, Italy

    Giuseppe De Luca

  3. Department of Interventional Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

    Maurits T. Dirksen & Marteen A. Vink

  4. Assistance Publique-Hopitaux de Paris Cochin Hospital, Paris 5 Medical School Rene Descartes University and INSERM Unite 780 Avenir, Paris, France

    Christian Spaulding

  5. The Heart Center, Rigshospitalet, Copenhagen, Denmark

    Henning Kelbæk

  6. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

    Martin Schalij & Bas van der Hoeven

  7. Cardiac Department, Skejby Hospital, Skejby, Denmark

    Leif Thuesen

  8. Department of Cardiology, University Hospital Basel, Basel, Switzerland

    Christoph Kaiser

  9. Division of Cardiology, San Camillo Hospital, Rome, Italy

    Carmine Musto & Roberto Violini

  10. Ospedale Santa Maria Annunziata, Bagno a Ripoli, Florence, Italy

    Tania Chechi & Gaia Spaziani

  11. Hemodynamics and Interventional Cardiology Unit, University Hospital Virgen del Rocio, Seville, Spain

    Luis Salvador Diaz de la Llera

  12. Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy

    Vincenzo Pasceri

  13. Division of Cardiology, “S.G. Moscati”, Avellino, Italy

    Emilio Di Lorenzo

  14. Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands

    Harry Suryapranata

  15. Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA

    Gregg W. Stone

Authors
  1. Giuseppe De Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurits T. Dirksen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Spaulding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henning Kelbæk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Schalij
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leif Thuesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bas van der Hoeven
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marteen A. Vink
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christoph Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carmine Musto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tania Chechi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gaia Spaziani
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Luis Salvador Diaz de la Llera
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Vincenzo Pasceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Emilio Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Roberto Violini
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Harry Suryapranata
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Gregg W. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe De Luca.

Additional information

For the DESERT cooperation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Luca, G., Dirksen, M.T., Spaulding, C. et al. Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation. Clin Res Cardiol 103, 685–699 (2014). https://doi.org/10.1007/s00392-014-0702-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-014-0702-6

Keywords

Search

Navigation